Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. (Q34126365)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Chi L

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Rebello SS

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gagnon A

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

101-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

In vivo models of arterial thrombosis and thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Role of tissue factor in embryonic blood vessel development.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Physiological consequences of loss of plasminogen activator gene function in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A murine model of myocardial microvascular thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Role of the thrombin receptor in development and evidence for a second receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Generation and characterization of urokinase receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Canine hemophilia B resulting from a point mutation with unusual consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A murine model of factor XI deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A dual thrombin receptor system for platelet activation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Rat model of arterial thrombosis induced by ferric chloride

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIa–Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Experimental models of coronary artery restenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Defective platelet activation in G alpha(q)-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Effects of Disruption of The Plasminogen Gene on Thrombosis, Growth, and Health in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A critical reappraisal of the bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Mice lacking factor VII develop normally but suffer fatal perinatal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Prothrombin activation in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Prothrombin deficiency results in embryonic and neonatal lethality in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Blood-clotting mechanisms of nonhuman primates. Choice of the baboon model to simulate man.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Gene therapy for arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

A factor IX-deficient mouse model for hemophilia B gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Antithrombotic Effects of Orally Active Synthetic Antagonist of Activated Factor X in Nonhuman Primates

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2800%2900095-2

7 January 2021

10.1016/S1056-8719(00)00095-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11150738%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference